The Dividend ETF Quietly Delivering Double-Digit Returns While Most Investors Aren't Paying Attention

The Schwab U.S. Dividend Equity ETF (SCHD) is up 26% over the past year, excluding dividends, as investors rotate toward non-tech stocks, according to the article. Technology is less than 10% of the fund, whose largest listed sector allocations include healthcare at 20.7% and consumer staples at 20.4%. The fund yields 3.2%, has a blended P/E below 20 and a 0.06% expense ratio; Schwab has increased its distribution by more than 550% since the fund began in late 2011.

Analysis

The useful signal is factor rotation, not a fundamental upgrade to the named holdings. SCHD bundles lower-tech exposure with value, dividend, and sector tilts; relative performance will therefore depend on breadth, rates, and sector earnings—not simply whether AI enthusiasm fades. The article’s “fair valuation” case is incomplete without current constituent weights, forward earnings revisions, and comparison with the S&P 500 on a like-for-like basis. A trailing rally also raises the risk that the easy catch-up has already occurred.

Second-order effects are mixed. TXN is not insulated from technology cycles merely because the ETF has little tech exposure, and analog demand can lag AI-led semiconductor investment. CVX adds commodity and capital-allocation sensitivity; KO and PG offer defensive cash flows but can be vulnerable if real yields rise or input costs pressure margins. The ETF’s diversification from mega-cap growth is useful, but its sector concentration can replace one crowded exposure with several cyclical or rate-sensitive ones.

Over 1–3 months, watch relative flows, breadth, real yields, and earnings-revision diffusion. Over 6–18 months, sustained non-tech earnings growth would support the rotation; renewed AI capex productivity and earnings upgrades could restore mega-cap leadership. The contrarian risk is treating a recent performance gap as durable mean reversion. Falsify the rotation thesis if SCHD continues to lag QQQ as market breadth narrows and tech earnings revisions reaccelerate; falsify the income/defensive thesis if real yields rise alongside deteriorating constituent payout or earnings coverage.

Key Decisions for Investors

• Treat SCHD as a portfolio diversifier, not a standalone AI-short thesis. If reducing mega-cap concentration is the objective, build exposure in stages rather than extrapolating its recent relative performance.
• For a tactical expression, consider a modest, beta-aware long SCHD / short QQQ relative-value position only after breadth and non-tech earnings revisions confirm; define risk on the spread, since an AI-led earnings acceleration can quickly reverse it. No price target is justified by the supplied information.
• Before increasing the position, verify current holdings and weights, forward earnings revisions, distribution coverage, valuation versus comparable indices, and fund flows. The article’s aggregate valuation and distribution history do not establish current constituent-level value or future payout growth.
• Keep TXN, CVX, KO, and PG as distinct exposure checks rather than treating them as interchangeable dividend proxies: monitor analog demand and inventory for TXN, crude and capital returns for CVX, and volume/pricing versus input-cost trends for KO and PG.